Correction: VTX-PID as a novel recombinant immunoglobulin G–degrading enzyme (IdeS) for efficient AAV-based gene therapy in participants with neutralizing antibodies: results of the phase I first-in-human NAVIgATE study - Summary - MDSpire

Correction: VTX-PID as a novel recombinant immunoglobulin G–degrading enzyme (IdeS) for efficient AAV-based gene therapy in participants with neutralizing antibodies: results of the phase I first-in-human NAVIgATE study

  • By

  • Bernard Benichou

  • Rainard Fuhr

  • Elodie Vernadal

  • Sonia Valero

  • Blanche Tamarit

  • Veronica Ferrer

  • Gloria Gonzalez-Aseguinolaza

  • Anne Douar

  • Marc Froissart

  • Annelise Brossel

  • Simone Floettmann

  • Francesca Del Bene

  • Céline Bouquet

  • Jean-Philippe Combal

  • June 17, 2026

  • 0 min

Share

Objective:

To correct errors in the original publication regarding the VTX-PID enzyme and its application in AAV-based gene therapy.

Approach:
    Key Findings:
    • Figure 4C was corrected to reflect the accurate threshold of negativity.
    • Acknowledgments were updated to include writing assistance.
    Interpretation:

    The article has been updated to correct previously published errors.

    Conclusion:

    The original version of the article has been updated to reflect these corrections.

    Sources:

Original Source(s)

Correction: VTX-PID as a novel recombinant immunoglobulin G–degrading enzyme (IdeS) for efficient AAV-based gene therapy in participants with neutralizing antibodies: results of the phase I first-in-human NAVIgATE study

  • by Bernard Benichou, Rainard Fuhr, Elodie Vernadal, Sonia Valero, Blanche Tamarit, Veronica Ferrer, Gloria Gonzalez-Aseguinolaza, Anne Douar, Marc Froissart, Annelise Brossel, Simone Floettmann, Francesca Del Bene, Céline Bouquet, Jean-Philippe Combal

  • June 17, 2026

Related Content

Decoding the reproductive microbiome: enabling clinical and biological insights through machine and deep learning

Case Report: rapid exacerbation of autoimmune hemolysis and severe immune - mediated thrombocytopenia induced by piperacillin – tazobactam

CX3CR1 and CCR2: dynamic myeloid cell states across inflammatory diseases with implications for oral health and disease